Open an account

Guided Therapeutics

GTHP · OTC

$0.19+$0.03 (+18.75%)TodayMarket closed ·
Prev close $0.16

About GTHP

Guided Therapeutics, Inc. is a medical technology company, which engages in developing medical devices. The company is headquartered in Norcross, Georgia and currently employs 4 full-time employees. The firm is focused on developing medical devices that have the potential to improve healthcare. The Company’s primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light. LuViva is designed to provide a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva is designed to improve patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care.

Employees
4
Headquarters
Norcross, Georgia
Listed
Jul 1, 1997
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
guidedinc.com

GTHP key statistics

Market cap
18.34M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
31.87K
Volume
154.21K
Open price
$0.16
High today
$0.195
Low today
$0.155
52 Week high
$0.54
52 Week low
$0.15

Guided Therapeutics (GTHP) at a glance

Guided Therapeutics (GTHP) last traded at $0.19, with a market cap of 18.34M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.155 and $0.195. The current price is 22.6% above the day's low and 2.6% below its high.

Volume so far is 154.21K shares, above the average of 31.87K shares a day.

Over the past year Guided Therapeutics has ranged from $0.15 to $0.54, and now sits 10% of the way up that range.

Guided Therapeutics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q4 FY25 it reported -$0.01 per share against an estimate of $0.00.

GTHP earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 8.5% on average.

  1. Q1 FY01: reported -$17,920,000.00 per share against an estimate of -$20,236,800.00
  2. Q2 FY01: reported -$10,240,000.00 per share against an estimate of -$13,708,800.00
  3. Q3 FY01: reported -$9,600,000.00 per share against an estimate of -$9,792,000.00
  4. Q4 FY01: reported -$10,880,000.00 per share against an estimate of -$11,097,600.00
  5. Q2 FY02: reported -$18,560,000.00 per share against an estimate of -$18,931,200.00
  6. Q3 FY23: reported -$0.01 per share against an estimate of $0.00
  7. Q1 FY24: reported -$0.01 per share against an estimate of $0.00
  8. Q4 FY25: reported -$0.01 per share against an estimate of $0.00

GTHP news

  • Press releaseBusiness Wire

    Guided Therapeutics Reaches Collaborative Agreement with Türkiye’s Ministry of Health to Become Primary Screening Test for Cervical Cancer

  • Press releaseBusiness Wire

    Guided Therapeutics Receives $80,000 Payment as Fourth Installment of $700,000 Purchase Order with Chinese Distributor

  • Press releaseBusiness Wire

    Guided Therapeutics Announces New Agreement with Distribution Partner Yuanshuo Medical Instruments Corporation

  • Press releaseBusiness Wire

    Guided Therapeutics Files Premarket Approval Application Clinical Report with FDA

  • Press releaseBusiness Wire

    Guided Therapeutics Provides Updates on FDA Application Study Results, 2025 Earnings Increase and Successful Warrant Offering

  • Press releaseBusiness Wire

    Analysis of Guided Therapeutics' FDA Study Data Reveals Compelling Clinical Need for LuViva

  • Press releaseBusiness Wire

    Guided Therapeutics Receives $88,000 Payment as Third Installment of $700,000 Purchase Order with Chinese Distributor

  • Press releaseBusiness Wire

    Guided Therapeutics Inks Initial $200,000 Deal with New Distribution Partner Yuanshuo Medical Instruments Corporation

Similar companies

Companies in the same industry as Guided Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.